Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation

Abstract

ObjectiveTo examine the impact of schizophrenia, its treatment and treatment-related adverse events related to antipsychotics, on quality of life from the perspective of schizophrenia patients and laypersons.MethodsHealth state descriptions for stable schizophrenia, extra pyramidal symptoms (EPS), hyperprolactinemia, diabetes, weight gain and relapse were developed based on a review of the literature and expert opinion. The quality of life impact of each health state was elicited using a time trade-off instrument administered by interview to 49 stable schizophrenia patients and 75 laypersons. Regression techniques were employed to examine the importance of subject characteristics on health-related utility scores.ResultsPatients and laypersons completed the interview in similar times. Stable schizophrenia had the highest mean utility (0.87 and 0.92 for laypersons and patients respectively), while relapse (0.48 and 0.60) had the lowest mean utility. Of the treatment-related adverse events, EPS had the lowest mean utility (0.57 and 0.72, respectively). Age, gender and PANSS score did not influence the utility results independently of health state. On average, patient utilities are 0.077 points higher than utilities derived from laypersons, although the ranking was similar between the two groups.ConclusionEvents associated with schizophrenia and treatment of schizophrenia can bring about a significant detriment in patient quality of life, with relapse having the largest negative impact. Results indicate that patients with stable schizophrenia are less willing to trade years of life to avoid schizophrenia-related symptoms compared to laypersons. Both sets of respondents showed equal ability to complete the questionnaire.

Translating genomic research into care for people with schizophrenia in China

“…As is commonly observed in studies of disability, patients scored illness as being less severe than did family members (Briggs et al, 2008).…”

Quality of Life in Psychosis: Prevalence and Associated Factors in a Nigerian Clinical Population

“…In addition, self evaluations of the constructs of quality of life by people with psychiatric disorders may lack reliability because of the presence of psychopathological symptoms as well as poor awareness of the disease (Browne et al 1996). Although, there are reports that people in stable phases of psychotic illnesses can reliably assess their health states even by using cognitively demanding methods (Briggs et al 2008), there are also consistent findings that people with schizophrenia in stable remission tend to overestimate their health utility than healthy people (Fan et al 2007) or professionals (Herrman et al 2002) would.…”

Economic evaluation of the use of a pharmacogenetic diagnostic test in schizophrenia

“…The health state utilities used in the model are presented in Table 3. The utilities of the different health states and the disutilities applied if ADEs occurred were taken from a direct utility elicitation study performed in the UK [34]. Patients that experienced treatment failure under risperidone treatment in the model would usually start a second-line treatment.…”